Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.67 |
| ▸ | CTSL | P07711 | 2/20 | 0.67 |
| ▸ | CTSB | P07858 | 2/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.67 |
| ▸ | CTSK | P43235 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | TYR | P14679 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372270 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL220648 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL26661077 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL479010 | 1.00 | TACR1 (0.68) | TACR1ITGB3ITGA2BCTSLCTSB | |
| Hypochlorous Acid SCHEMBL7368156 | 0.97 | TACR1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL5391083 | 0.94 | ITGB3 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL12052836 | 0.94 | TACR1 (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL1702159 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL221300 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL10507966 | 0.94 | ECE1 (0.65) | TACR1ITGB3ITGA2BCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-20140135509-A1 | Process for the Preparation of Benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and Intermediates in the Process | ASTRAZENECA AB (SE) | 2014-05-15 | — | — | US | claimed |
| EP-2707363-A1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | AstraZeneca AB (SE) | 2014-03-19 | — | — | EP | claimed |
| CN-103534245-A | A process for the preparation of benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and intermediates in the process | ASTRAZENECA AB | 2014-01-22 | — | — | CN | claimed |
| WO-2012158099-A1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | claimed |
| CN-100429223-C | Process for producing cyclo (D-phenylpropyl-D-group) dipeptide | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2008-10-29 | — | — | CN | claimed |
| CN-1557834-A | Process for producing cyclo (D-phenylpropyl-D-group) dipeptide | �Ͼ���ҵ��ѧ | 2004-12-29 | — | — | CN | claimed |
| EP-0024182-B1 | THERMO-STABLE MICRO-ORGANISM AND PROTEOLYTIC ENZYME PREPARED THEREFROM, AND PROCESSES FOR THE PREPARATION OF THE MICRO-ORGANISM AND THE PROTEOLYTIC ENZYME | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1986-05-07 | — | — | EP | claimed |
| US-4480036-A | Proteolytic enzyme | DEVELOPMENT FINANCE CORPORATION (NZ) | 1984-10-30 | — | — | US | claimed |
| EP-0024182-A2 | Thermo-stable micro-organism and proteolytic enzyme prepared therefrom, and processes for the preparation of the micro-organism and the proteolytic enzyme | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1981-02-25 | — | — | EP | claimed |
| JP-57193437-A | — | — | None | — | — | JP | disclosed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| WO-2025095479-A1 | NOVEL PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND AND USE THEREOF | 서울대학교병원 | 2025-05-08 | — | — | WO | disclosed |
| EP-0024182-A2 | Thermo-stable micro-organism and proteolytic enzyme prepared therefrom, and processes for the preparation of the micro-organism and the proteolytic enzyme | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1981-02-25 | — | — | EP | disclosed |
| US-4124703-A | Luliberin analogs | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-11-07 | — | — | US | disclosed |
| US-4100274-A | LULIBERIN ANTAGONIST | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-07-11 | — | — | US | disclosed |
| US-4064270-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | TACR1 4246/4885ITGB3 1965/4885ITGA2B 3131/4885 |
| US-20140135509-A1 | Process for the Preparation of Benzyl [(3aS,4R,6S,6aR)-6-hydroxy-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol]-4-yl]carbamate and Intermediates in the Process | CYP4X1, CYP4B1, CBR3 | TACR1 666/4885ITGB3 3065/4885ITGA2B 3841/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | TACR1 3107/4885ITGB3 2779/4885ITGA2B 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.